|Bid||0.00 x 1300|
|Ask||0.00 x 1800|
|Day's Range||18.45 - 19.11|
|52 Week Range||10.86 - 23.91|
|Beta (5Y Monthly)||2.02|
|PE Ratio (TTM)||7.98|
|Earnings Date||Nov 04, 2020 - Nov 09, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||30.44|
The biosimilar leader crushed it during the first half of 2020. Will it finally earn a higher market valuation?
Coherus BioSciences (CHRS) delivered earnings and revenue surprises of 169.23% and 35.23%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
– Second Quarter UDENYCA® Net Sales of $135.7 Million – – Net Income of $59.0 Million – – Non-GAAP Net Income of $68.3 Million –REDWOOD CITY, Calif., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today reviewed corporate events and reported financial results for the quarter ended June 30, 2020.Second Quarter 2020 and Recent Corporate Highlights * Net product revenue for the second quarter of 2020 was $135.7 million, and net income was $59.0 million, or $0.70 per share on a diluted basis. * Non-GAAP income during the second quarter of 2020 was $68.3 million, or $0.81 per share on a diluted basis. * Cash flow from operating activities was $60.2 million for the second quarter of 2020. * The Healthcare Distribution Alliance recognized Coherus’ successful launch of UDENYCA® (pegfilgrastim-cbqv) by awarding the 2019 Diana Award in the category for Best New Product Introductions in the Biotechnology Pharmaceutical Product sector. * The Company appointed veteran healthcare leader, Kimberly Tzoumakas, J.D. to its Board of Directors.Second Quarter 2020 Financial ResultsNet product revenue for the second quarter of 2020 was $135.7 million. Net product revenue included a favorable revision of the Company’s prior period payer rebate estimate of $13.3 million recorded in the second quarter of 2020. Cost of goods sold for the second quarter of 2020 was $10.1 million, resulting in a gross profit margin of 93%.Research and development (R&D) expense for the second quarter of 2020 was $26.2 million, as compared to $18.9 million for the same period in 2019. R&D expense for the six months ended June 30, 2020 was $59.3 million, as compared to $37.7 million for the same period in 2019. The increase in R&D expense in both periods was primarily due to preparations for the biologics license application (BLA) filing of CHS-1420, Coherus’ biosimilar to Humira® (adalimumab), and to the manufacturing scale-up to initiate planned clinical trials in 2021 for CHS-2020, Coherus’ biosimilar to Eylea® (aflibercept).Selling, general and administrative (SG&A) expense for the second quarter of 2020 was $34.1 million, as compared to $36.5 million for the same period in 2019. SG&A expense for the six months ended June 30, 2020 was $69.4 million, as compared to $69.1 million for the same period in 2019. Cash, cash equivalents and investments in marketable securities for the second quarter increased to $456.5 million as of June 30, 2020, as compared to $193.3 million as of March 31, 2020 and $177.7 million as of December 31, 2019. The increase in the second quarter of 2020 is primarily due to generating $60.2 million in net cash from operating activities and receiving $222.8 million in net proceeds from issuing convertible debt notes due 2026 in April 2020, which was offset by purchasing $18.2 million in capped call options related to the convertible notes.Net income for the second quarter of 2020 was a $59.0 million, or $0.70 per share on a diluted basis, compared to $23.6 million, or $0.32 per share on a diluted basis for the same period in 2019.Non-GAAP net income for the second quarter of 2020 was $68.3 million, or $0.81 per share on a diluted basis, compared to non-GAAP income of $31.5 million, or $0.43 per share on a diluted basis for the same period in 2019. See “Non-GAAP Financial Measures” below for a discussion on how the Company calculates non-GAAP net income and a reconciliation to the most directly comparable GAAP measure.Guidance for the Remainder of 2020Coherus will continue to lay the foundation for long-term growth across its three therapeutic areas:Oncology * Deliver continued market success with UDENYCA® (pegfilgrastim-cbqv) against all Neulasta® dosage forms, while maintaining average selling price (“ASP”) discipline, leveraging the validated branded-biosimilar strategy of offering a robust value proposition across all key customer segments. * Advance the Company’s biosimilar candidate to Avastin® (bevacizumab) in-licensed from Innovent toward an expected 351(k) BLA submission with the U.S. FDA in 2021, depending on the outcome and the timing of required interactions with the FDA in completing a three-way pharmacokinetic (“PK”) study, as well as completing additional analytical similarity exercises.Ophthalmology * Facilitate Bioeq’s resubmission of a 351(k) BLA with the FDA for the biosimilar candidate to Lucentis® (ranibizumab) in the second half of 2020. * Advance the Company’s internally developed CHS-2020 biosimilar candidate to Eylea® (aflibercept) to an expected Phase 3 clinical trial initiation in 2021, with launch projected in 2025, if approved.Immunology * Complete certain manufacturing, regulatory and development activities for the Company’s internally developed Humira® (adalimumab) biosimilar, CHS-1420, and file the 351(k) BLA in the fourth quarter of 2020. The Company expects this timing will enable a projected market entry in the United States on or after July 1, 2023, if approved.Financial Guidance * R&D and SG&A expenses combined together are expected to range between $285 million and $310 million for the full fiscal year 2020, excluding upfront or milestone payments from any potential new collaborations, consistent with prior quarter guidance.Conference Call InformationWhen: Thursday, August 6, 2020 starting at 4:30 p.m. ETWebcast: at https://investors.coherus.com. The conference call will be broadcast live in listen-only mode on the Company’s investor relations website at https://investors.coherus.com/. If you would like to ask a question, the dial in number for the conference call is 844-452-6826 (Toll-Free U.S. and Canada) or 765-507-2587 (International).Conference ID: 4956327Please dial-in 15 minutes early to ensure a timely connection to the call.Second quarter 2020 financial results are posted on the Coherus website at https://investors.coherus.com/. The webcast will be archived on the Coherus website.About Coherus BioSciences, Inc.Coherus is a leading biologics company that develops and commercializes its own high-quality biosimilar therapeutics as well as those of others seeking capable access to the United States market. Composed of a team of proven industry veterans with world-class expertise in product development and commercialization, Coherus is positioned as a leader in the global biosimilar marketplace. Headquartered in the United States, Coherus is committed to reducing healthcare system costs and expanding patient access of essential therapeutics.Coherus has commercialized UDENYCA® (pegfilgrastim-cbqv) in the United States and received regulatory approval for UDENYCA® in the European Union. Coherus is advancing late-stage clinical products CHS-1420, a Humira® (adalimumab) biosimilar, Bioeq’s Lucentis® (ranibizumab) biosimilar and Innovent’s Avastin® (bevacizumab) biosimilar towards commercialization. The Company is also advancing early-stage clinical products including, CHS-2020, an Eylea® (aflibercept) biosimilar. For additional information, please visit www.coherus.com.Forward-Looking StatementsExcept for the historical information contained herein, the matters set forth in this press release are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, Coherus’ ability to lay the foundation for long-term growth across its three therapeutic areas; Coherus’ ability to deliver continued market success with UDENYCA® (pegfilgrastim-cbqv) against all Neulasta® dosage forms, Coherus’ ability to maintain average selling price (“ASP”) discipline, leveraging the validated branded-biosimilar strategy of offering a robust value proposition across all key customer segments; Coherus’ ability to advance its Innovent Avastin® (bevacizumab) oncology biosimilar candidate in-licensed from Innovent by completing a three-way PK study, as well as completing additional analytical similarity exercises; Coherus’ ability to submit a 351(k) BLA with the FDA in 2021 for the Innovent biosimilar candidate to Avastin®; Coherus’ ability to launch Innovent’s biosimilar candidate to Avastin® in the United States; Coherus’ ability to facilitate Bioeq’s resubmission of a 351(k) BLA with the FDA for the ophthalmology biosimilar candidate to Lucentis® (ranibizumab) in the second half of 2020 and Coherus’ ability to launch the product, if approved; Coherus’ ability to advance CHS-2020 an Eylea® (aflibercept) ophthalmology biosimilar currently in preclinical development by initiating an expected Phase 3 clinical trial in 2021, with launch projected in 2025, if approved; Coherus’ ability to complete certain manufacturing, regulatory and development activities for CHS-1420, a Humira® (adalimumab) immunology biosimilar, with an anticipated filing of a 351(k) BLA in the fourth quarter of 2020; Coherus’ ability to have a projected market entry in the United States on or after July 1, 2023 for CHS-1420; and Coherus’ ability to meet its R&D and SG&A expenses guidance for the full fiscal year 2020. Such forward-looking statements involve substantial risks and uncertainties that could cause Coherus’ actual results, performance or achievements to differ significantly from any future results, performance or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the risks and uncertainties inherent in the clinical drug development process; the risks and uncertainties of the regulatory approval process, including the timing of Coherus’ regulatory filings; the risk that Coherus is unable to complete commercial transactions and other matters that could affect the availability or commercial potential of Coherus’ biosimilar drug candidates; and the risks and uncertainties of possible patent litigation. All forward-looking statements contained in this press release speak only as of the date on which they were made. Coherus undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Coherus’ business in general, see Coherus’ Annual Report on Form 10-K for the year ended December 31, 2019, filed with the Securities and Exchange Commission on February 27, 2020, its Quarterly Report on Form 10-Q for the three and six months ended June 30, 2020, filed with the Securities and Exchange Commission on August 6, 2020 and its future periodic reports to be filed with the Securities and Exchange Commission. Our results for the quarter ended June 30, 2020 are not necessarily indicative of our operating results for any future periods.UDENYCA® is a trademark of Coherus BioSciences, Inc.Neulasta® and Onpro® are registered trademarks of Amgen Inc. Avastin® and Lucentis® are registered trademarks of Genentech, Inc. Humira® is a registered trademark of AbbVie Inc. Eylea® is a registered trademark of Regeneron Pharmaceuticals, Inc. Coherus BioSciences, Inc. Condensed Consolidated Statements of Operations (in thousands, except share and per share data) (unaudited) Three Months Ended Six Months Ended June 30, June 30, 2020 2019 2020 2019 Revenue: Net product revenue$135,674 $83,433 $251,854 $120,531 Operating expenses: Cost of goods sold 10,139 601 16,994 2,826 Research and development 26,173 18,883 59,280 37,672 Selling, general and administrative 34,052 36,456 69,402 69,139 Total operating expenses 70,364 55,940 145,676 109,637 Income from operations 65,310 27,493 106,178 10,894 Interest expense (5,408) (4,433) (9,839) (8,649) Other income, net 423 558 491 1,369 Net income before income taxes 60,325 23,618 96,830 3,614 Income tax provision 1,294 51 2,227 51 Net income$59,031 $23,567 $94,603 $3,563 Net income per share: Basic$0.83 $0.34 $1.33 $0.05 Diluted$0.70 $0.32 $1.20 $0.05 Weighted-average number of shares used in computing net income per share: Basic 71,099,773 69,479,016 70,880,979 69,310,791 Diluted 88,660,280 72,963,972 83,775,353 72,281,564 Coherus BioSciences, Inc. Condensed Consolidated Balance Sheets (in thousands) (unaudited) June 30, December 31, 2020 2019 Assets Cash and cash equivalents$224,617 $177,668 Investments in marketable securities 231,882 — Trade receivables, net 172,486 141,992 Inventory 80,984 55,071 Other assets 46,642 34,196 Total assets$756,611 $408,927 Liabilities and Stockholders’ Equity Accrued rebates, fees and reserve$66,229 $51,120 Convertible notes due 2022 79,198 78,542 Convertible notes due 2022 - related parties 26,399 26,181 Convertible notes due 2026 222,409 — Term loan 74,059 73,663 Other liabilities 74,940 74,207 Total stockholders' equity 213,377 105,214 Total liabilities and stockholders’ equity$756,611 $408,927 Coherus BioSciences, Inc. Condensed Consolidated Cash Flow (in thousands) (unaudited) Three Months Ended Six Months Ended June 30, June 30, 2020 2019 2020 2019 Cash, cash equivalents and restricted cash at beginning of the period$ 193,692 $ 82,350 $ 177,908 $ 73,191 Net cash provided by (used in) operating activities$ 60,191 $ 12,677 $ 73,668 $ (44,306) Purchases of investments in marketable securities (231,864) — (231,864) (14,864) Proceeds from maturities of investments in marketable securities 9,000 9,000 Upfront license fee payment to Innovent (5,000) - (5,000) — Cash used in other investing activities (2,384) (182) (4,000) (517) Net cash provided by (used in) investing activities$ (239,248) $ 8,818 $ (240,864) $ (6,381) Proceeds from issuance of Convertible Notes due 2026, net of issuance costs 222,830 — 222,830 — Purchase of capped call options related to convertible notes due 2026 (18,170) — (18,170) — Proceeds from term loan, net of issuance costs — 185 - 73,061 Proceeds from common stock offering, net of underwriters discounts, commissions and offering costs — — — 8,153 Proceeds from issuance of common stock upon exercise of stock options 3,302 947 8,105 1,395 Proceeds from purchase under the employee stock purchase plan 2,557 1,878 2,557 1,878 Cash used in other financing activities (97) — (977) — Net cash provided by financing activities$ 210,422 $ 3,010 $ 214,345 $ 84,487 Effect of exchange rate changes on cash — (93) — (229) Net increase in cash, cash equivalents and restricted cash$ 31,365 $ 24,412 $ 47,149 $ 33,571 Cash, cash equivalents and restricted cash at end of the period$ 225,057 $ 106,762 $ 225,057 $ 106,762 Reconciliation of cash, cash equivalents, and restricted cash Cash and cash equivalents 224,617 105,927 224,617 105,927 Restricted cash 440 835 440 835 Cash, cash equivalents and restricted cash$ 225,057 $ 106,762 $ 225,057 $ 106,762 Non-GAAP Financial MeasuresTo supplement the financial results presented in accordance with GAAP, Coherus has also included in this press release non-GAAP net income, and the related per share measures, which exclude from net income, and the related per share measures, stock-based compensation expense, upfront and milestone payments under the license agreements and the related income tax effect of those non-GAAP adjustments. These non-GAAP financial measures are not prepared in accordance with GAAP, do not serve as an alternative to GAAP and may be calculated differently than similar non-GAAP financial information disclosed by other companies. Coherus encourages investors to carefully consider its results under GAAP, as well as its supplemental non-GAAP financial information and the reconciliation between these presentations set forth below, to more fully understand Coherus’ business.Coherus believes that the presentation of these non-GAAP financial measures provides useful supplementary information to, and facilitates additional analysis by, investors. In particular, Coherus believes that these non-GAAP financial measures, when considered together with its financial information prepared in accordance with GAAP, can enhance investors’ and analysts’ ability to meaningfully compare Coherus’ results from period to period, and to identify operating trends in Coherus’ business. Coherus also regularly uses these non-GAAP financial measures internally to understand, manage and evaluate its business and to make operating decisions. Coherus BioSciences, Inc. Reconciliation of GAAP Net Income to Non-GAAP Net Income (in thousands, except share and per share data) (unaudited) Three Months Ended Six Months Ended June 30, June 30, 2020 2019 2020 2019 GAAP net income$59,031 $23,567 $94,603 $3,563 Adjustments: Stock based compensation expense 9,425 7,991 18,980 17,486 Upfront payment under the license agreement with Innovent — — 5,000 — Income tax effect of the above adjustments (202) (17) (552) (247) Non-GAAP net income$68,254 $31,541 $118,031 $20,802 GAAP net income per share, basic$0.83 $0.34 $1.33 $0.05 GAAP net income per share, diluted$0.70 $0.32 $1.20 $0.05 Non-GAAP net income per share, basic$0.96 $0.45 $1.67 $0.30 Non-GAAP net income per share, diluted$0.81 $0.43 $1.48 $0.29 Shares used in computing basic net income per share 71,099,773 69,479,016 70,880,979 69,310,791 Shares used in computing diluted net income per share 88,660,280 72,963,972 83,775,353 72,281,564 ContactDavid S. Arrington Investor Relations & Corporate Affairs Coherus BioSciences, Inc. firstname.lastname@example.org +1 (650) 395-0196